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Intravenous glucose tolerance testPassive and proactive coping styles are associated with marked differences in behavioral and neuroendocrine
responses. Previous studies revealed that the passive individuals are more prone to hyperinsulineamia.
Likewise, we hypothesize that different coping styles may require different drugs to treat this. We tested this
by treating passive and proactive rats (Roman Low Avoidance and Roman High Avoidance rats respectively)
with either Rosiglitazone or with RU486. After eight days of treatment we performed and intravenous glucose
tolerance test (IVGTT) and we compared the insulin and glucose levels with those measured during the IVGTT
at baseline. Rosiglitazone improved insulin levels during an IVGTT in both passive and proactive coping styles.
RU486, however, lowered insulin levels only in rats with a passive coping style. This study suggests that
insight in the neuroendocrine differences between passive and proactive coping styles may provide an extra
impulse to improve treatment of insulin resistance, since it allows the application of drugs targeted at the
individual.ology, University of Groningen
632345; fax:+3150363 2331
n.dijk@rug.nl (G. van Dijk),
@rug.nl (A.J.W. Scheurink).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
The signiﬁcance of personality, stress coping and other psychosocial
factors for the development of insulin resistance and type 2 diabetes has
becomemore evident in recentyears (FeldmanandSteptoe, 2003; Sovio
et al., 2007; Yancura et al., 2006). The mechanisms underlying the
interaction between psychosocial factors and metabolic pathologies,
however, remain to be elucidated. One approach is to study these
mechanisms in rodent lines with divergent stress coping and person-
ality proﬁles. In our previous studies we have shown that rats selected
for a passive strategy to cope with stress, the so-called Roman Low
avoidance rats (RLA), have a higher sensitivity to develop signs
indicative of the metabolic syndrome than proactively coping animals,
the Roman High avoidance rats (Boersma et al., 2009). We conﬁrmed
these ﬁndings in passive and proactive littermates from an out bred
wild-type Groningen (WTG) rat population. These WTG rats display a
more moderate dispersion of coping styles and in these rats we again
showed that more passive individuals had consistently higher prone-
ness to develop insulin resistance than proactive individuals (Boersma
et al., 2010).
Taken together, these studies indicate that the coping style of an
individual plays an important role in the development of metabolic
derangements. Likewise one may argue that different coping styles,
.may also respond differently to different treatments for metabolic
disorders such as type 2 diabetes and the metabolic syndrome. We
should therefore focus on custom made treatments for passive and
proactive coping styles for treatment of insulin resistance. To this end,
we decided to test the potential beneﬁcial effects of two different drug
treatments for hyperinsulineamia, Rosiglitazone and RU486, in both
passively and proactively coping rats of the Roman selection lines.
In our ﬁrst set of experiments focused on the effects of
Rosiglitazone, a peroxisome proliferator-activated receptor gamma
agonist, known to directly induce translocation of the glucose
transporter type 4 (GLUT4) to the membrane (Saltiel and Olefsky,
1996; Spiegelman, 1998), and thereby increasing insulin sensitivity of
the insulin receptor. This oral anti-diabetic agent is a commonly used
treatment strategy for the metabolic syndrome and it has a good
success rate in patients with type 2 diabetes (reviewed in Krentz and
Bailey, 2005). Since Rosiglitazone directly improves the insulin
signaling cascade circumventing possible differences in insulin
receptor sensitivity, we assume that treatment with this drug will
be equally effective in passive and proactive individuals.
The second drug, RU486, is speciﬁcally targeted at treating the
hyperinsulineamia observed in passive coping style (Boersma et al.,
2009). RU486 is a glucocorticoid receptor antagonist predominantly
used in the treatment of diabetes associated with Cushing syndrome
and glucocorticoid secreting tumors (Johanssen and Allolio, 2007). This
therapeutic agent may be interesting since passively coping rats are
characterized by moderate elevated glucocorticoid levels (Aubry et al.,
1995; Boersma et al., 2009; Fernandez-Teruel et al., 2002; Gentsch et al.,
1982). Elevated glucocorticoid levels, in turn, are associated with an
increase susceptability for insulin resistance. If elevated glucocorticoid
Table 1
Body weight (BW), food intake (FI) and water intake (WI) of RLA and RHA rats before
treatment and after treatment with either Rosiglitazone or RU486. aIndicates a
signiﬁcant difference with RLA rats (within treatment) Pb0.05 bIndicates a signiﬁcant
difference with baseline condition (within a strain) Pb0.05.
Rosiglitazone RU486
RLA RHA RLA RHA
Baseline BW (g) 435.3±6.7 401.7±9.9 433.3±7.3 399.8±10.0
Change in BW (g) 43.5±6.3b 47.5±5.4b 40.6±6.9b 53.2±7.3b
Baseline FI (kcal/day) 97.48±3.87 96.45±3.21 96.81±3.51 97.32±4.02
Treatment FI (kcal/day) 98.70±4.44 97.17±2.50 90.10±2.17b 89.73±2.52b
Baseline WI (ml/day) 41.78±2.11 34.80±1.11a 40.62±2.05 34.32±1.86a
TreatmentWI (ml/day) 41.28±2.28 35.86±2.31a 40.73±2.62 33.58±4.06a
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resistance in RLA rats, we expect that blocking the glucocorticoid action
with a glucocorticoid receptor antagonist, RU486, would obliterate
differences in glucose homeostasis among RHA and RLA rats. Treatment
with RU486 would therefore speciﬁcally improve insulin signaling in
the RLA rats.
In summary, in the present study we hypothesize that different
personalities may require different drugs for treatment of hyperinsu-
lineamia. To this end, we treated proactive and passive rats with two
different drugs and measured glucose and insulin responses to an
intravenous glucose tolerance test before and after treatment. We
hypothesize that Rosiglitazone will increase insulin sensitivity in both
personality types and that RU486 will only be effective in the passive
coping style.
2. Materials and methods
2.1. Animals
Adult male Roman High (n=16) and Roman Low Avoidance rats
(n=16) with body weights between 300 and 400 g were used. The
rats were obtained from a breeding colony at the Clinical Psycho-
pharmacology Unit (APSI), University of Geneva, Switzerland. The
Roman High and Low Avoidance rats (RHA and RLA, respectively)
were originally selected by Bignami (Bignami, 1965) on the basis of
their performance in a two-way active avoidance test. Rats with the
most extreme coping styles were identiﬁed and selectively bred for
many generations. This resulted in two sub-strains: Roman Low
Avoidance rats with an extremely passive coping style and Roman
High Avoidance rats with a proactive coping strategy (Driscoll et al.,
1983). The passive coping RLA is characterized by low aggression
levels, ﬂexible behavioral patterns and a passive stress response,
whereas the proactive RHA is characterized by high levels of
aggression, rigid behavioral patterns and a proactive strategy towards
stressors (Steimer et al., 1997).
All rats were housed individually in standard cages (24×24×36 cm),
lab chow (Hope Farms, RMH-B knaagdier korrel, Arie Blok Diervoeding,
Woerden, NL) and water were available ad lib. The room was controlled
for temperatureandhumidity (T=20±2 °C,humidity60%)andwaskept
at a 12–12 h light–dark cycle (lights on=CT0). All animal experiments
were approved by the local animal care committee.
2.2. Surgery
The rats underwent surgery to place two indwelling jugular vein
catheters allowing continuous blood sampling in freely moving
animals. Rats were sedated using an isoﬂurane-O2/N2O gas anesthe-
sia. A silicon heart catheter (0.95 mm OD, 0.50 mm ID and 0.64 mm
OD, 0.28 ID) was inserted into the right jugular vein and kept in place
with a ligature. The catheter was pulled under the skin towards the
skull where it was connected to a metal bow. This metal bow was
ﬁxed to the skull with dental cement and 4 small screws. The same
procedure was repeated on the left side. During blood sampling or
infusions a piece of tubing could be attached to the metal bow, hereby
samples could be taken from conscious rats. In between experiments,
the catheter was ﬁlled with a PVP/heparin solution preventing blood
cloth formation in the catheter (Steffens, 1969a). The animals were
given 0.1 ml Finadine s.c. for analgesia and 0.25 ml penicillin s.c. to
prevent infection. After surgery the rats were allowed to recover for at
least 7 days.
2.3. Intravenous glucose tolerance test
After recovery from surgery, the rats were accustomed to the
infusion and blood sampling procedure before the actual onset of the
experiments (Steffens, 1969b). Then, an intravenous glucose toler-ance test (IVGTT)was performed tomeasure the baseline responses in
each individual animal. After the baseline IVGTT, the animals were
treated with either Rosiglitazone or RU486 for eight days. A second
IVGTT was performed at day 8, the last day of treatment. This within-
subject experimental set-up allowed us to use each individual rat as
its own control. During the intravenous glucose tolerance test (IVGTT)
an infusion of 15 mg/min glucose was given in 3 ml saline solution
over a 30 min period. This is a physiological dose that mimics the
glucose response after a large meal (Strubbe and Bouman, 1978).
The experiments were performed in the middle of the light phase,
between CT4 and CT6. Rats were denied access to their food from the
beginning of the light phase until the end of the IVGTT; food was
removed at CT0. Two baseline blood samples were taken before the
start of the infusion (t=−15 and t=−5 min). The glucose infusion
was given between t=0 and 30 min, during and after infusion blood
samples were taken at time points 5, 10, 15, 20, 25, 30, 35, 40, and
50 min. A total volume of 2.8 ml blood was taken and the loss of
volume was substituted by saline infusion. Blood samples were kept
on ice and stored in ﬁles with 10 μl EDTA (0.09 g/ml). For glucose
determination 50 μl of full blood with 450 μl heparin solution (2%)
was stored at −20 °C. The remaining blood was centrifuged for
15 min and plasma was stored for insulin determination.2.4. Rosiglitazone treatment
Eight RHA and eight RLA rats were treated with a dose of 4 mg/kg/
day (Kramer et al., 2001) Rosiglitazone (AstraZenica, Mölndal,
Sweden) for 8 consecutive days. Rosiglitazone was administered in
the drinking water. The water intake of the rats was monitored for a
week before the start of the experiment, and the concentration of
Rosiglitazone was adjusted accordingly. Since RLA rats drink generally
more than the RHA rats (Boersma et al., 2009 and Table 1), the actual
concentration of Rosiglitazone was calculated on the basis of baseline
water intake of each individual rat. On average, the RLA rats received
50±3 mg/L and RHA rats 57±2 mg/L Rosiglitazone solution. During
treatment water intake of the rats did not change, which means that
that each individual rat received 4 mg/kg/day of Rosiglitazone daily.2.5. RU486 treatment
Eight RHA and eight RLA rats were treated with 20 mg/kg/day
(Diaz et al., 2001) RU486 (11β-[p-(Dimethylamino)phenyl]-17β-
hydroxy-17-(1-propynyl)estra-4,9-dien-3-one) (mifepristone,
Sigma-Aldrich Chemie, Zwijndrecht) for 8 consecutive days. RU486
was given subcutaneously at CT2 and CT14, both injections contained
10 mg/kg RU486 in 0.5 ml saline. Before the start of the treatment the
rats were accustomed to the subcutaneous injections procedure; they
received a single saline injection (0.5 ml/kg) for 4 consecutive days.
The efﬁciency of the RU486 treatment was assessed by measuring
corticosteron levels in the baseline plasma samples prior to the IVGTT.
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The rats were sacriﬁced after 8 days of treatment, one day after the
last IVGTT. Three hours before lights off, blood samples were taken
directly from the heart under isoﬂurane-O2/N2O gas anesthesia for
determination of blood glucose, plasma insulin and leptin levels.
Animals were hereafter sacriﬁced using an overdose of pentobarbital.
Epididymal and retroperitoneal fat pads and the liver were taken out
and weighed. The skin with the subcutaneous fat was removed from
the carcass. Liver, skin, and carcasses were dried at 80 °C for 5 days.
Fat content was determined by extracting the fat from tissue using a
petroleum based Soxlet fat extractor. After fat extraction the tissue
was dried for 5 days again. The relation between dry tissue weight
before and after fat extraction provides information on the fat content
of the tissue.2.7. Chemical analyses
Plasma levels of insulin and leptin were measured using
commercial radioimmunoassay (RIA) kits (Linco Research). Blood
glucose levels were determined using the ferry-cyanide method in a
Technicon auto analyzer. Plasma corticosteron levels were measured
using a commercial radioimmunoassay (RIA) (Biomedics).2.8. Statistical analysis
Data are expressed as averages with standard error of the mean.
Differences in food and water intake, body weight and baseline
plasma levels between strains were determined using one-way
ANOVA using strain as the between subjects factor. Differences in
insulin and glucose levels before, during and after the IVGTT were
examined using repeated measures ANOVA, again using strain as the
between subjects factor. The area under the curves of both glucose
and insulin responses (t=0 till t=30 min) were calculated and
reported as the average area under the curve (AUC) with the standard
error of the mean. The differences between the strains were
determined using one-way ANOVA. The statistical differences be-
tween the strains in corticosteron levels before and after the
treatment were assessed using a repeated measures ANOVA, with
the strain as the between subjects factor, and time as the within
subjects factor. A conﬁdence interval of 5% was used.Fig. 1. Glucose and insulin levels before, during and after an intravenous glucose tolerance te
A: Glucose response in RLA rats. B: Glucose response in RHA rats. C: Insulin response in RLA
symbols represent samples after Rosiglitazone treatment. * indicates a signiﬁcant differenc3. Results
3.1. Body weight and food intake
Table 1 displays body weights and food intake of RLA and RHA rats
during the baseline period and after treatment with either Rosiglita-
zone or RU486. At the start of the experiments, the RLA rats were
somewhat but not signiﬁcantly heavier than the RHA rats (P=0.072).
Both Rosiglitazone and RU486 treatment reduced bodyweights in RLA
and RHA rats (for Rosiglitazone RM-ANOVA F3,21=7,258; RLA
P=0.021; RHA p=0.007, and for RU486 RM-ANOVA F3,21=11,362
RLA P=0.012; RHA P=0.001). There were no differences in food
intake between RLA and RHA rats under baseline conditions.
Treatment with RU486 signiﬁcantly reduced food intake in both
strains (RM-ANOVA F1,21=12,232, P=0.016). Treatment with Rosi-
glitazone had no effect on the food intake. There were no differences
between the strains in the effects of either Rosiglitazone or RU486 on
both body weight and food intake. At baseline water intake was
signiﬁcantly higher in the RLA rats compared to RHA rats
(F3,21=9.234, Pb0.01). Treatment with either RU486 or Rosiglitazone
did not affect water intake.
3.2. Intravenous glucose tolerance test
Figs. 1 and 2 display the glucose and insulin responses to an IVGTT
in chow fed RLA and RHA rats at baseline and after treatment with
RU486 or Rosiglitazone. Fig. 3 provides the areas under the curve
(AUC) of the insulin response.
There were no differences in glucose levels between RLA and RHA
rats under any of the tested conditions, nor did either treatment affect
glucose levels. Baseline plasma insulin levels were signiﬁcantly higher
in RLA rats in comparison to RHA rats (F1,21=11.095, P=0.003).
Treatment with Rosiglitazone signiﬁcantly reduced the insulin
response to an IVGTT in both RLA and RHA rats (at time points
t=5, 10, 20, 25 and 30 min, Pb0.05). Also the AUC for the insulin
response was signiﬁcantly reduced after Rosiglitazone treatment in
both strains (F1,21=5,242, Pb0.05).
Treatment with RU486 signiﬁcantly lowered the insulin response
to an IVGTT in the RLA rats but not in the RHA rats. The reduction in
the RLA rats was signiﬁcant at time points t=5, 10, 20, 25 and 30 min
(Fig. 2C)(ANOVA F1,5=8.210, Pb0.05). Also the area under the insulin
curve was signiﬁcantly lower in RLA rats after treatment with RU486
(F1,21=4,356, Pb0.05).st in RLA and RHA rats under baseline conditions and after treatment with Rosiglitazone.
rats. D: Insulin response in RHA rats. Black symbols represent baseline samples, white
e (Pb0.05).
Fig. 2. Glucose and insulin levels before, during and after an intravenous glucose tolerance test in RLA and RHA rats under baseline conditions and after treatment with RU486.
A: Glucose response in RLA rats. B: Glucose response in RHA rats. C: Insulin response in RLA rats. D: Insulin response in RHA rats. Black symbols represent baseline samples. White
symbols represent samples after RU486 treatment. * indicates a signiﬁcant difference (Pb0.05).
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calculated the differences in the area under the curve before and after
treatment (day 0 versus day 8) for each individual rat. The differencesFig. 3. The area under the curve of the insulin responses (t=0 until t=30) during a
30 min infusion of glucose (15 mg/min) under baseline and treated conditions. RLA
and RHA rats A: The response in rats under baseline and Rosiglitazone treated
conditions. B: The response in rats under baseline and RU486 treated conditions.
White bars represent baseline conditions, hatched bars represent treated conditions.
* indicates a signiﬁcant difference (Pb0.05).between the RLA and the RHA rats with respect to the effect of RU486
was signiﬁcant (reduction in the area under the insulin curve in RLA
rats: −41.6±16.6, in RHA rats: −3.9±8.3 ng/ml insulin* 30 min,
ANOVA F1,11=5.654, Pb0.05). There were no signiﬁcant differences
between the strains with respect to the effect of Rosiglitazone
(reduction in the area under the insulin curve for RHA rats: −33.6±
15.6 and for RLA rats: −51.4±21.3 ng/ml insulin* 30 min, ANOVA
F1,11=2.238, P=0.089).3.3. Corticosterone levels
Fig. 4 displays the plasma corticosteron levels at baseline and after
treatment with RU486 or Rosiglitazone. Baseline corticosteron was
signiﬁcantly elevated in the RLA rats when compared to the RHA rats
(F3,21=5,242, Pb0.01). Treatment with RU486 signiﬁcantly lowered
plasma corticosteron levels in both RLA and RHA rats (F3,21=3,842,
Pb0.01). The reduction in corticosteron levels after treatment was
signiﬁcantly larger in the RLA rats compared to the RHA rats (ANOVA
F1,11=6.342, Pb0.05). After treatment with RU486 there were no
differences between the strains in corticosteron levels. Rosiglitazone
treatment did not change corticosteron levels in either strain.Fig. 4. Corticosteron levels in RLA and RHA before and after treatment with either
Rosiglitazone or RU486. White bars represent untreated baseline conditions, hatched
bars represent treatment conditions. * indicates a signiﬁcant difference (Pb0.05).
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Body compositionwas determined at the last day of treatment; the
results of the analysis are summarized in Table 2. The body weights of
the RLA rats were signiﬁcantly higher compared to the RHA rats in
both treatment groups (F3,25=2.925, Pb0.05). Total fat mass of RLA
rats was higher that the fat mass of RHA after both treatments
(F3,25=3.052, P=0.032). RU486-treated RLA rats had more adipose
tissue distributed in their epididymal compartment when compared
to RU486 treated RHA rats (F3,25=4.851, P=0.009). There was no
difference in the amount of retroperitoneal fat mass between RLA and
RHA rats treated with RU486. After treatment with Rosiglitazone the
RLA rats had more fat distributed in their epididymal compartment
than RHA rats (F3,25=3.899, P=0.018). The amount of retroperito-
neal adipose tissue after Rosiglitazone treatment was not different
between RLA and RHA rats. Within each strain, there were no
differences in the body composition of rats treated with Rosiglitazone
compared to those treated with RU486.
4. Discussion
The present study investigated the effectiveness of two different
drugs for treating hyperinsulineamia in rat strains that were selected
for either a passive or a proactive coping style. It was found that
RU486 was only effective in reducing plasma insulin levels in
passively coping rats whereas the effect of Rosiglitazone on insulin
was similar in both rat strains.
For the general anti-diabetic agent, Rosiglitazone, we expected a
comparable effect in passive and proactive individuals. Our study
conﬁrmed this: treatment with Rosiglitazone reduced the insulin
response to an IVGTT in both RLA and RHA rats. As mentioned before,
passive individuals are characterized by a hyperinsulineamic response
to an IVGTT (Boersma et al., 2009). Therefore, the effect of Rosiglitazone
on plasma insulin seemed somewhat larger in the passive RLA rats.
Treatment with Rosiglitazone was very effective in reducing the insulin
response in theRLA rats to a level thatwas similar to that of theRHArats.
It was not surprising that Rosiglitazone improved insulin responses in
both the passive and proactive individuals in the present study.
Thiazolidinediones, like Rosiglitazone, are thought to increase insulin
sensitivity by activation of PPAR gamma, which in turn leads to an
increased translocation of the glucose transporter 4 (GLUT4). This
increased availability of GLUT 4 then facilitates glucose transport into
the cell. Several studies have shown the beneﬁcial effects of Rosiglita-
zone (Kramer et al., 2001) although the exact mechanism by which the
drug may increase GLUT4 translocation in skeletal muscle cell remains
to be elucidated. It seems that Rosiglitazone affects the insulin receptor
cascade directly andmay circumventmost of the differences in origin of
hyperinsulineamia inn the RLA rat.
The second drug that was tested in the present study is RU486,
commonly used for treating insulin resistance in patients in which
type 2 diabetes is secondary to chronically increased glucocorticoid
levels, such as Cushing syndrome (Johanssen and Allolio, 2007).Table 2
Body fat distribution of RLA and RHA rats treated with either Rosiglitazone or RU486.
aIndicates a signiﬁcant difference with RLA rats (within treatment) Pb0.05.
Rosiglitazone RU486
RLA RHA RLA RHA
Body weight (g) 391±8.9 354±9.6a 392±8.2 344±9.7a
Lean body mass (g) 186±4.1 177±6.3 187±3.6 171±4.0
Total body fat (%) 11.7±1.77 9.5±0.76a 11.1±0.77 9.5±0.77a
Epidydimal fat (g) 5.1±0.62 3.3±0.16a 4.5±0.23 3.3±0.24a
Retroperitoneal fat (g) 6.7±1.16 6.3±0.67 6.6±0.57 6.2±0.57
Subcutaneous fat (g) 25.4±4.9 18.3±4.2 23.7±2.3 19.6±2.25
Liver weight (g) 17.6±1.3 16.9±1.5 18.4±1.6 16.5±1.8
Leptin (ng/ml) 4.0±0.42 3.5±0.58 3.9±0.45 3.8±0.66Evidence in literature suggests that there are moderate differences
between passive and proactive individuals in HPA-axis activity and
baseline glucocorticoid levels (Gentsch et al., 1982). Therefore, we
hypothesized that treatment with RU486 might be particularly
effective in lowering plasma insulin levels in the passively coping
RLA rats. The data obtained in the present study supported this
hypothesis. Treatment with RU486 signiﬁcantly lowered the insulin
response to an IVGTT in the passively coping RLA rats and had no
effect in proactive RHA rats.
Since RU486 was effective in attenuating hyperinsulineamia in the
passively coping rat one may assume that the effect was secondary to
the effect of RU486 on circulating glucocorticoid levels. Indeed, the
data of the present study revealed that: 1) corticosterone levels are
increased in untreated RLA rats and 2) that treatment of RLA rats with
RU486 normalized corticosterone (and insulin) to a level comparable
to the proactive RHA rats. The data also suggest that moderately
increased corticosterone levels may serve as a useful treatment
strategy for hyperinsulineamia in passive coping individuals. The
underlying mechanisms are not well understood. Glucocorticoids are
thought to induce insulin resistance through several pathways. First,
glucocorticoids decrease the sensitivity of muscle glucose uptake to
insulin by decreasing translocation of GLUT4 transporters to the
membrane. Second, glucocorticoids can inhibit the rate of glucose
phosphorylation (Dimitriadis et al., 1997). Finally, glucocorticoids
affect insulin sensitivity indirectly by stimulation of distribution of
adipose tissue in the visceral compartment (reviewed in (Peeke and
Chrousos, 1995)).
Even though, the average body weight of the rats from the two
strains did not differ in a statistically signiﬁcant manner, RLA were
heavier, and this is consistent with previous observations (Boersma et
al., 2010; Rossi et al., 1997). Treatment with both RU486 and
Rosiglitazone signiﬁcantly lowered body weight in both the RHA
and RLA rats but the difference between the strains remained
unchanged throughout the experimental period. The decrease in
bodyweight after RU486 can, in part, be explained by the concomitant
decrease in food intake during treatment (Trocki et al., 1995). In
contrast, Rosiglitazone treatment did not affect daily food intake
suggesting that the reduction in body weight is secondary to
increased energy expenditure rather than being caused by reduced
energy intake. Interestingly, at baseline water intakewas higher in the
RLA, however, treatment with either RU486 or Rosiglitazone did not
affect water intake in either strain. This suggests that the hyper-
insulineamic response in the RLA rats is not due to differences in
water intake. Glucose levels either at baseline or during the IVGTT
were not different for RLA and RHA rats. Treatment with either
Rosiglitazone or RU486 did not affect glucose levels.
Total and epidydimal fat mass were signiﬁcantly different between
RHA and RLA rats after both treatment with RU486 and Rosiglitazone.
Due to the within-subject design of the present study, we have no
data on the body composition in untreated animals. However, in a
previous study with (untreated) RLA and RHA rats of similar age
(Boersma et al., 2009, 2010), we already observed that total and
epidydimal fat mass are signiﬁcantly higher in RLA in comparison
with RHA rats. This means that the observed differences in body fat
distribution in the present study are presumably not caused by direct
effects of either RU486 or Rosiglitazone. Finally, there were no
differences in liver weights or leptin levels between the RLA and RHA
rats after either treatment with Rosiglitazone or RU486.
In conclusion, the data of the present study reveal that Rosiglita-
zone improves the insulin response to an IVGTT independent of the
coping styles of the individual. In contrast, RU486, improves
hyperinsulineamia solely in the passive coping style, by targeting
the speciﬁc hormonal characteristics of this coping style. We conclude
that insight in the neuroendocrine differences between different
coping styles may provide an extra and important impulse to improve
treatment of hyperinsulineamia.
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